John Patrick Shannon Jr - Jan 29, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 29, 2022
Transactions value $
-$559,808
Form type
4
Date filed
8/2/2024, 05:22 PM
Previous filing
Jan 5, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +250K +11.52% $0.00 2.42M Aug 1, 2024 Direct F1, F2
transaction XERS Common Stock Tax liability -$33.1K -15.7K -0.65% $2.11 2.4M Jan 29, 2022 Direct F3, F4
transaction XERS Common Stock Tax liability -$15.8K -7.5K -0.31% $2.11 2.4M Jan 31, 2022 Direct F3, F5
transaction XERS Common Stock Tax liability -$46.3K -41.3K -1.72% $1.12 2.36M Jan 3, 2023 Direct F3, F6
transaction XERS Common Stock Tax liability -$29.5K -23.4K -0.99% $1.26 2.33M Jan 29, 2023 Direct F3, F7
transaction XERS Common Stock Tax liability -$12.3K -9.88K -0.42% $1.24 2.32M Jan 31, 2023 Direct F3, F8
transaction XERS Common Stock Tax liability -$91.5K -40.8K -1.76% $2.24 2.28M Jan 3, 2024 Direct F3, F9
transaction XERS Common Stock Tax liability -$58.9K -22.2K -0.97% $2.66 2.26M Jan 29, 2024 Direct F3, F10
transaction XERS Common Stock Tax liability -$272K -111K -4.9% $2.46 2.15M Jan 31, 2024 Direct F3, F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +300K $0.00 300K Aug 1, 2024 Common Stock 300K $2.43 Direct F12, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F2 These shares include 11,037 shares that were purchased on June 30, 2024, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
F3 This transaction is being reported late due to administrative oversight.
F4 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
F5 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
F6 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
F7 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
F8 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
F9 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
F10 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
F11 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.
F12 The award will vest in full on the two-year anniversary of the grant date.
F13 Upon exercise, the Stock Appreciation Right will be settled in cash.

Remarks:

Chief Executive Officer and Director